Original ArticlesTargeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer
Introduction
Pancreatic cancer remains one of the most aggressive tumors with an extremely poor prognosis and is estimated to become the second leading cause of cancer-related death by 2030 [1,2]. This dramatic outcome is related to the lack of efficient therapeutic tools, early diagnostic markers, and high resistance to chemotherapy.
Abundant desmoplastic reaction is a prominent feature of pancreatic cancer and constitutes up to 80% of the total tumor volume. It is characterized by the presence mainly of cancer-associated fibroblasts (CAFs), but also of immune cells, vasculature, and extracellular matrix (ECM). These stroma characteristics contribute to pancreatic cancer aggressivity and therapeutic failure because they promote tumor progression, invasion and resistance to chemotherapies [3,4]. Once activated, CAFs express alpha smooth muscle actin (αSMA) and secrete ECM and soluble factors (e.g., growth and inflammatory factors) that stimulate tumor growth and mediate inflammation. In preclinical studies, stroma disruption, by direct CAF targeting (hedgehog signaling inhibitors) [5] or by ECM enzymatic digestion (hyaluronidase), results in tumor inhibition and increases drug delivery [6]; however, controversial or disappointing results were reported by clinical trials. Moreover, recent studies have questioned CAF role in pancreatic tumor maintenance and highlighted the need of caution when targeting CAFs [[7], [8], [9]]. Indeed, several evidences indicate that there are different CAF subtypes with different functions [10,11]. Therefore, characterization of these subtypes is needed to enable the specific targeting of CAFs with pro-tumor features.
Neuregulins (NRGs) are large polypeptide growth factors that are part of the EGF family of proteins. They are encoded by four genes (NRG1-4) that are subject to extensive alternative mRNA splicing, leading to more than 30 variants grouped in six types (I-VI) with a distinct N-terminal part. NRG1 and 2 are both HER3 and HER4 ligands and have at least two splice alternatives in their EGF-like domains, resulting in α and β isoforms. NRG1 β has higher binding affinity for HER3 through HER2-dependent recruitment [12]. NRG3 and 4 bind only to HER4. Most isoforms are synthetized as transmembrane molecules with the EGF-like domain in the extracellular space and are released as soluble factors by cell surface proteases. Binding to the EGF-like domain of NRG1 promotes HER3 or HER4 conformational changes, leading to their dimerization and activation that result in the phosphorylation of downstream signaling molecules. Several evidences indicate that NRG1 contributes to the development and progression of different tumor types, such as breast, prostate or pancreatic cancer [[13], [14], [15], [16]]. High NRG1 expression has been correlated with poor prognosis in breast cancer, head and neck squamous cell carcinoma and pancreatic cancer [[13], [14], [15]]. In addition, NRG1 downregulation by antisense oligonucleotides, or NRG1 signaling inhibition by competitive binding of a shorter HER3 isoform reduces breast cancer cell proliferation and migration [16,17]. Furthermore, the crosstalk between NRG1 and HER3 is involved in resistance to chemo- and targeted therapies through the maintenance of oncogenic signaling pathways [18].
Several studies reported that not only EGF family growth factors but also their receptors play an important role in pancreatic cancer development. Expression of EGFR, HER2 and HER3 has been examined in pancreatic ductal carcinoma and correlated with advanced disease and poor prognosis [[19], [20], [21], [22]]. HER4 expression has not been examined as extensively and its prognostic value is not known.
Disruption of intracellular communications between stromal and cancer cells could affect tumor proliferation and represents an interesting therapeutic strategy. In this context, we hypothesized that targeting NRG, which we here show to be secreted both by CAFs and tumor cells, could be a novel therapy to overcome CAF-triggered tumor growth in pancreatic cancer. Here, we investigated, in in vivo and in vitro co-culture of pancreatic cancer cells and CAFs, the therapeutic potential of an original monoclonal antibody (7E3) that targets NRG1 Ig-like domain. We show promising tumor growth inhibitory effects of this antibody which promotes antibody dependent cellular cytotoxicity (ADCC) in NRG1-permeated pancreatic cancer cells and in NRG1-positive CAFs and blocks NRG1-mediated HER3 activation and downstream signaling pathway induction.
Section snippets
Cell lines and reagents
The BxPC-3, CFPAC-1, HPAC, AsPC-1, SW1990, MiaPaCa-2 and MCF7 cancer cell lines were obtained from ATCC (Rockville, MD, USA) and cultured following the ATCC recommendations. The identity of cell lines was confirmed by genetics authentification test (Eurofins, Ebersberg). BxPC-3-Luc, HPAC-Luc, shHER3 BxPC-3 and shluc BxPC-3 cells were generated previously in the laboratory [23]. Stably-transfected AsPC-1-Mock (vector alone) and AsPC-1-NRG1 cells were obtained as previously described for
NRG1 regulates pancreatic tumor growth in an autocrine and paracrine manner
RT-qPCR expression analysis showed NRG1 expression in 17/33 (51.5%) pancreatic tumor samples (Fig. 1A). Then, NRG1β1 gene expression was assessed in five KRAS-mutated pancreatic cancer cell lines and one KRAS-wild type cell line (BxPC-3). BxPC3, CFPAC and SW1990 cells expressed NRG1, whereas HPAC, MiaPaca2 and AsPC-1 did not (Fig. 1B). As positive control, we developed a NRG1 positive cell derived of AsPC-1 (AsPC-1-NRG1 cells). As negative control, we used normal pancreatic cells (NPC). By
Discussion
The 7E3 antibody blocked NRG1-dependent tumor cell growth by decreasing HER3 activity and expression level and promoting ADCC activation against tumors cells and micro-environment. This mechanism can contribute to the therapeutic effect observed in mice and can be explained by its original binding. Indeed, our antibody exhibited a high degree of specificity and affinity for NRG1 IgG-like domain, and did not prevent the NRG1 binding to HER3. This explains 7E3 ability to target NRG1 already
Funding
This work was supported by grants from the Ligue Nationale Contre le Cancer-Comité de l’Hérault, France, from the LabEx MabImprove (ANR-10-LABX-53-01), France, from the SIRIC Montpellier Cancer, “INCa-DGOS-INSERM 6045”, France, from the Cancéropole Grand Sud Ouest, France.
Conflicts of interest
Charline Ogier, Christel Larbouret, Thierry Chardès and André Pèlegrin are inventors in the anti-NRG1 mAb patents related to this work. The other authors declare no conflict of interest.
Acknowledgments
We thank S. Bousquié, for technical assistance and N. Robin for providing pancreatic tumors. We thank the Montpellier RIO Imaging and the RHEM histology facilities.
References (50)
- et al.
Pancreatic cancer
Lancet
(2011) - et al.
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival
Canc. Cell
(2014) - et al.
Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2
J. Biol. Chem.
(1998) - et al.
EMT and dissemination precede pancreatic tumor formation
Cell
(2012) - et al.
Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody in patients with advanced non-small cell lung cancer
EBioMedicine
(2015) - et al.
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States
Canc. Res.
(2014) - et al.
Role of tissue stroma in cancer cell invasion
J. Pathol.
(2003) The biology and function of fibroblasts in cancer
Nat. Rev. Canc.
(2016)- et al.
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Science
(2009) - et al.
Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer
Clin. Canc. Res.
(2016)
The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal
Canc. Metastasis Rev.
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Proc. Natl. Acad. Sci. U. S. A
The biology and function of fibroblasts in cancer
Nat. Rev. Canc.
Fibroblast heterogeneity in the cancer wound
J. Exp. Med.
Neuregulins and cancer
Clin. Canc. Res.
Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma
Cancer
Expression and differential signaling of heregulins in pancreatic cancer cells
Int. J. Canc.
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer
Oncogene
A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4
Canc. Res.
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
Oncotarget
Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression
Clin. Canc. Res.
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
Canc. Biol. Ther.
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
Anticancer Res.
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
Am. J. Clin. Oncol.
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Oncotarget
Cited by (39)
Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer
2022, Radiotherapy and OncologyCitation Excerpt :Likewise, PI3K/AKT signaling in association with enhanced HER3 expression was shown to be the underlying mechanism of resistance to EGFR TK inhibitors in NSCLC [46]. Moreover, a study by Ogier et al. demonstrated that targeting of NRG-HER3 axis using NRG neutralizing antibody is an effective therapeutic approach for pancreatic carcinoma [47]. In the present study we showed that anti-EGFR antibody cetuximab does not block AKT activity after irradiation in lung cancer cells.
Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?
2022, European Journal of PharmacologyCitation Excerpt :Scriptaid, a selective inhibitor of HDACs 1/3/8, also reported to could suppress TGFβ-mediated CAF differentiation, reduce ECM secretion, and impair cell invasion in murine model of melanoma (Kim et al., 2018). Targeting neuregulin (NRG1), a highly expressed molecules on CAFs, using antibodies such as 7E3 is another mechanism that could reduce the activity of CAFs in pancreatic tumors (Ogier et al., 2018). MicroRNAs are another tool that could be recruited to shut down the activity of CAFs in TME.
Targeting CAFs to overcome anticancer therapeutic resistance
2022, Trends in CancerBio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
2021, Biomedicine and Pharmacotherapy